Table 3:

Ongoing Clinical Trials of Anti-Oxidants and Anti-Inflammatory Agents in Sickle Cell Disease

Drug	Study Title	Mechanism of Action	Clinical Phase	NCT Number	Sponsor
N-acetyl cysteine	A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease (NACinSCD)	Anti-oxidant (increased glutathione)	Phase 1/2	NCT01800526	Bloodworks; University of Washington
Omega-3 fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA))	Omega-3 Fatty Acids in Sickle Cell Disease	Anti-inflammatory	Phase 1/2 /	NCT02947100;	NIGMS; Thomas Jefferson University; Solutex GC, S.L.
Azithromycin	Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease; A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease	Anti-inflamatory agent (antibiotic)	Phase 1; Phase 1	NCT02960503; NCT02630394	Vanderbilt University; University of Mississippi Medical Center
Canakinumab	Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia	Anti-inflammatory agent (anti-IL-1β)	Phase 2	NCT02961218	Novartis Pharmaceuticals
Omega-3 fatty acid (DHA)	Sickle Cell Omega-3 Treatment Trial (SCOT Trial) (SCOT)	Anti-inflammatory	Phase 3	NCT02604368	Sancillio and Company, Inc
Atorvastatin	Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (ENDO)	Anti-inflammatory; pleiotropic (statin)	Phase 2	NCT01732718	University of North Carolina, Chapel Hill
Mometasone Furoate	Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (IMPROVE)	Anti-inflammatory (steroid)	Phase 2	NCT02061202	Icahn School of Medicine at Mount Sinai
Montelukast	Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia	Anti-inflammatory (leukotriene receptor antagonist)	Phase 2	NCT01960413	Vanderbilt University Medical Center